Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4), are revolutionary progress in cancer therapy. Here, PDCD1 is linked to cancer.